ReviewPeerJ2025
Role of hypothalamus function in metabolic diseases and its potential mechanisms.
Review in PeerJ, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Phytochemicals and Irisin as Multi-Target Regulators of Adipose Tissue Browning and Metabolic Reprogramming: Synergies with GLP-1 Pathways.Antioxidants (Basel, Switzerland) · 2026Review
- Anthocyanins Modulation of Gut Microbiota to Reverse Obesity-Driven Inflammation and Insulin Resistance.Nutrients · 2025Review
- An overview of hypopituitarism's causes.Frontiers in endocrinology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The hypothalamus, a crucial neuroendocrine regulatory center, plays a significant role in the occurrence and development of metabolic diseases. Recent advances in molecular biology and imaging technology have facilitated a better understanding of the central role of the hypothalamus in the dysregulation of regulatory mechanisms. This review examines the involvement of hypothalamic nuclei in metabolic diseases, the direct effects of glucose and fat on the hypothalamus, and the influence of the hypothalamus on metabolic diseases. Furthermore, it investigates the role of the hypothalamus in the emergence and progression of metabolic disorders, including obesity and diabetes. Finally, it outlines the current research progress in treating metabolic diseases through hypothalamus regulation. This study could provide a theoretical basis for understanding the pathophysiological mechanisms of metabolic diseases and development of new treatment strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.